[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593730":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":52,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A-IST","EXPERIMENTAL","Porcine-ATG : 15 mg\u002Fkg\u002Fday IV ×5 days. Cyclosporine : 3-5 mg\u002Fkg\u002Fday (adjusted to trough 100-200 μg\u002FL). Hetrombopag: 15 mg daily.",[13],"Drug: Dose-attenuated IST and Hetrombopag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Dose-attenuated IST and Hetrombopag","Porcine-ATG : 15 mg\u002Fkg\u002Fday IV ×5 days. Cyclosporine : 3-5 mg\u002Fkg\u002Fday (adjusted to trough 100-200 μg\u002FL). Hetrombopag: 15 mg daily for 24weeks.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jun Shi, PhD","Institute of Hematology & Blood Diseases Hospital, CAMS","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Jianping Li, MD","CONTACT","+8613820961539","lijianping@ihcams.ac.cn",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Jingyu Zhao, MPH","+8613752253515","zhaojingyu@ihcams.ac.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":20,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Red Blood Cell Diseases Center","RECRUITING","Tianjin","Tianjin Municipality","China",{"type":44,"coordinates":45},"Point",[46,47],117.17667,39.14222,{"lat":47,"lon":46},[50],{"name":28,"role":29,"phone":51,"phoneExt":20,"email":31},"13820961539",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100593730",false,"NCT07010237","Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe\u002FSevere Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety","Inclusion Criteria:\n\n* Clinical diagnosis of VSAA\u002FSAA.\n* Age ≥65 years.\n* Completion of all screening assessments.\n* Must be able to swallow tablets.\n* Signed informed consent (by patient or legal guardian if patient is incapacitated).\n\nExclusion Criteria:\n\n* Clonal cytogenetic abnormalities (excluding isolated -Y or +8).\n* Prior treatment with ATG\u002Fhigh-dose cyclophosphamide.\n* Prior cyclosporine\u002Ftacrolimus use \\>12 months.\n* Prior TPO-RA therapy \\>3 months.\n* Uncontrolled malignancies or conditions contraindicating ATG.\n* Severe organ dysfunction (e.g., creatinine ≥177 μmol\u002FL).\n* Investigator judgment of unsuitability.","ALL","65 Years",{"count":63,"type":64},65,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA\u002FSAA.",[70,71,72],"Sever Aplastic Anaemia","Elderly (People Aged 65 or More)","Immunosuppressive Treatment","2025-06-05",{"date":75,"type":76},"2025-06-08","ACTUAL",{"date":78,"type":76},"2025-02-01",{"date":80,"type":64},"2029-07-01",{"name":5,"class":6},1]